Corteva Inc (CTVA) Stock Forecast & Price Target

Corteva is supported by a compelling combination of a deep crop-protection pipeline, a strong biologics portfolio, and a leaner post-spin structure that should improve earnings power as new products, cost cuts, and better farmer economics flow through. Management’s 2029 EBITDA target of $1.45B-$1.65B appears achievable, with estimates near the top end helped by roughly $1B of sales uplift from new products and biologics, plus about $200M of added cost savings. Its roughly $0.5B net cash position expected by end-2026, along with about a 10% unlevered FCF yield and capacity for buybacks or M&A, reinforces a favorable fundamental outlook.

Corteva is facing a difficult fundamental setup because the crop protection market remains under pressure, with limited volume growth, generics-driven deflation, and management already assuming a 1% annual price decline during the 2027-2029 period. Its smaller post-spin portfolio may also weaken its negotiating power with large customers, particularly in Brazil, while softer farm income, lower corn prices, and a ~15% corn stocks-to-use ratio point to continued weakness in seeds and crop protection demand. On top of that, PFAS obligations and related settlement cash outflows could absorb liquidity, even as pro forma cash of $3.1B and debt of $1B still leave uncertainty around the expected ~$0.5B net cash position by the end of 2026.